{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:18:26Z","timestamp":1791555506855,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Biomarkers of Huntington\u2019s disease (HD) in cerebrospinal fluid (CSF) could be of value in elucidating the biology of this genetic neurodegenerative disease, as well as in the development of novel therapeutics. Deranged synaptic and immune function have been reported in HD, and concentrations of the synaptic protein neurogranin and the microglial protein TREM2 are increased in other neurodegenerative diseases. We therefore used ELISAs to quantify neurogranin and TREM2 in CSF samples from HD mutation carriers and controls. CSF neurogranin concentration was not significantly altered in HD compared to controls, nor was it significantly associated with disease burden score, total functional capacity or motor score. An apparent increase in CSF TREM2 in manifest HD was determined to be due to increasing TREM2 with age. After age adjustment, there was no significant alteration of TREM2 in either HD group, nor any association with motor, functional or cognitive score, or brain volume quantified by MRI. Both analyses were well-powered, and sample size calculations indicated that several thousand samples per group would be needed to prove that disease-associated alterations do in fact exist. We conclude that neither neurogranin nor TREM2 is a useful biofluid biomarker for disease processes in Huntington\u2019s disease.<\/jats:p>","DOI":"10.1038\/s41598-018-21788-x","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T06:51:31Z","timestamp":1520232691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cerebrospinal fluid neurogranin and TREM2 in Huntington\u2019s disease"],"prefix":"10.1038","volume":"8","author":[{"given":"Lauren M.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileanoir B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-7887","authenticated-orcid":false,"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,9]]},"reference":[{"key":"21788_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates, G. P. et al. Huntington disease. Nat Rev Dis Primers 1, 15005 (2015).","journal-title":"Nat Rev Dis Primers"},{"key":"21788_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.tins.2010.08.002","volume":"33","author":"AJ Milnerwood","year":"2010","unstructured":"Milnerwood, A. J. & Raymond, L. A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington\u2019s disease. Trends Neurosci 33, 513\u2013523 (2010).","journal-title":"Trends Neurosci"},{"key":"21788_CR3","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1021\/pr0700753","volume":"6","author":"A Dalrymple","year":"2007","unstructured":"Dalrymple, A. et al. Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6, 2833\u20132840 (2007).","journal-title":"J Proteome Res"},{"key":"21788_CR4","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bjorkqvist","year":"2008","unstructured":"Bjorkqvist, M. et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. The Journal of experimental medicine 205, 1869\u20131877 (2008).","journal-title":"The Journal of experimental medicine"},{"key":"21788_CR5","doi-asserted-by":"crossref","unstructured":"Traeger, U. et al. HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NFKB-pathway dysregulation. Brain 137, 819\u201333 (2014).","DOI":"10.1093\/brain\/awt355"},{"key":"21788_CR6","doi-asserted-by":"publisher","first-page":"Rrn1231","DOI":"10.1371\/currents.RRN1231","volume":"3","author":"E Wild","year":"2011","unstructured":"Wild, E. et al. Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS currents 3, Rrn1231 (2011).","journal-title":"PLoS currents"},{"key":"21788_CR7","doi-asserted-by":"publisher","first-page":"e0163479","DOI":"10.1371\/journal.pone.0163479","volume":"11","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues, F. B. et al. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington\u2019s Disease. PLoS One 11, e0163479 (2016).","journal-title":"PLoS One"},{"key":"21788_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neuron.2009.09.034","volume":"64","author":"M Bj\u00f6rkqvist","year":"2009","unstructured":"Bj\u00f6rkqvist, M., Wild, E. J. & Tabrizi, S. J. Harnessing immune alterations in neurodegenerative diseases. Neuron 64, 21\u201324 (2009).","journal-title":"Neuron"},{"key":"21788_CR9","unstructured":"National Institutes for Health. A Clinical Study in Subjects With Huntington\u2019s Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02215616. Accessed February 2018."},{"key":"21788_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JHD-170262","volume":"6","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues, F. B. & Wild, E. J. Clinical Trials Corner: September 2017. Journal of Huntington\u2019s disease 6, 255\u2013263 (2017).","journal-title":"Journal of Huntington\u2019s disease"},{"key":"21788_CR11","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1523\/JNEUROSCI.2213-04.2004","volume":"24","author":"KP Huang","year":"2004","unstructured":"Huang, K. P. et al. Neurogranin\/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. Journal of Neuroscience 24, 10660\u201310669 (2004).","journal-title":"Journal of Neuroscience"},{"key":"21788_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology 6, 131\u2013144 (2010).","journal-title":"Nature reviews. Neurology"},{"key":"21788_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh, R. et al. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurology 73, 561\u2013571 (2016).","journal-title":"JAMA neurology"},{"key":"21788_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington, H. et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology 86, 829\u2013835 (2016).","journal-title":"Neurology"},{"key":"21788_CR15","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00018-005-5084-5","volume":"62","author":"R Smith","year":"2005","unstructured":"Smith, R., Brundin, P. & Li, J.-Y. Synaptic dysfunction in Huntington\u2019s disease: a new perspective. Cellular and Molecular Life Sciences CMLS 62, 1901\u20131912 (2005).","journal-title":"Cellular and Molecular Life Sciences CMLS"},{"key":"21788_CR16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.drudis.2014.02.006","volume":"19","author":"MD Sepers","year":"2014","unstructured":"Sepers, M. D. & Raymond, L. A. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington\u2019s disease. Drug Discovery Today 19, 990\u2013996 (2014).","journal-title":"Drug Discovery Today"},{"key":"21788_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/hmg\/ddl013","volume":"15","author":"A Hodges","year":"2006","unstructured":"Hodges, A. et al. Regional and cellular gene expression changes in human Huntington\u2019s disease brain. Hum. Mol. Genet. 15, 965\u2013977 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"21788_CR18","doi-asserted-by":"publisher","first-page":"14424","DOI":"10.1073\/pnas.0703652104","volume":"104","author":"H Runne","year":"2007","unstructured":"Runne, H. et al. Analysis of potential transcriptomic biomarkers for Huntington\u2019s disease in peripheral blood. Proc. Natl. Acad. Sci. USA 104, 14424\u201314429 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"21788_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.imbio.2008.07.008","volume":"213","author":"O Sharif","year":"2008","unstructured":"Sharif, O. & Knapp, S. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213, 701\u2013713 (2008).","journal-title":"Immunobiology"},{"key":"21788_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1086\/342259","volume":"71","author":"J Paloneva","year":"2002","unstructured":"Paloneva, J. et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71, 656\u2013662 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"21788_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N. Engl. J. Med. 368, 107\u2013116 (2013).","journal-title":"N. Engl. J. Med."},{"key":"21788_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamaneurol.2013.6237","volume":"71","author":"J Cady","year":"2014","unstructured":"Cady, J. et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71, 449\u2013453 (2014).","journal-title":"JAMA Neurol"},{"key":"21788_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1326-8-19","volume":"8","author":"S Rayaprolu","year":"2013","unstructured":"Rayaprolu, S. et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson\u2019s disease. Mol Neurodegener 8, 19 (2013).","journal-title":"Mol Neurodegener"},{"key":"21788_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet, M. et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med 8, 466\u2013476 (2016).","journal-title":"EMBO Mol Med"},{"key":"21788_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave, A. et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Molecular Neurodegeneration 11, 3 (2016).","journal-title":"Molecular neurodegeneration"},{"key":"21788_CR26","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1177\/1352458515624558","volume":"22","author":"A Ohrfelt","year":"2016","unstructured":"Ohrfelt, A. et al. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler 22, 1587\u20131595 (2016).","journal-title":"Mult Scler"},{"key":"21788_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. The Lancet Neurology 16, 601\u2013609 (2017).","journal-title":"The Lancet. Neurology"},{"key":"21788_CR28","doi-asserted-by":"crossref","unstructured":"Rodrigues, F. B. et al. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease. Journal of Neurochemistry 139, 22\u201325 (2016).","DOI":"10.1111\/jnc.13719"},{"key":"21788_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-160196","volume":"5","author":"LM Byrne","year":"2016","unstructured":"Byrne, L. M. & Wild, E. J. Cerebrospinal Fluid Biomarkers for Huntington\u2019s Disease. Journal of Huntington\u2019s Disease 5, 1\u201313 (2016).","journal-title":"Journal of Huntington\u2019s disease"},{"key":"21788_CR30","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild, E. J. et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. The Journal of Clinical Investigation 125, 1979\u20131986 (2015).","journal-title":"The Journal of clinical investigation"},{"key":"21788_CR31","doi-asserted-by":"crossref","unstructured":"Huntington\u2019s disease study group. Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Huntington Study Group. Movement Disorders 11, 136\u2013142 (1996).","DOI":"10.1002\/mds.870110204"},{"key":"21788_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410410521","volume":"41","author":"JB Penney Jr","year":"1997","unstructured":"Penney, J. B. Jr, Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. CAG repeat number governs the development rate of pathology in Huntington\u2019s disease. Annals of neurology 41, 689\u2013692 (1997).","journal-title":"Annals of neurology"},{"key":"21788_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet. Neurology 12, 637\u2013649 (2013).","journal-title":"The Lancet. Neurology"},{"key":"21788_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1109\/42.668698","volume":"17","author":"JG Sled","year":"1998","unstructured":"Sled, J. G., Zijdenbos, A. P. & Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87\u201397 (1998).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"21788_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0169-2607(97)01803-8","volume":"53","author":"PA Freeborough","year":"1997","unstructured":"Freeborough, P. A., Fox, N. C. & Kitney, R. I. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput. Methods Programs Biomed. 53, 15\u201325 (1997).","journal-title":"Comput. Methods Programs Biomed."},{"key":"21788_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archneur.60.7.989","volume":"60","author":"RI Scahill","year":"2003","unstructured":"Scahill, R. I. et al. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60, 989\u2013994 (2003).","journal-title":"Arch Neurol"},{"key":"21788_CR37","first-page":"1483","volume":"22","author":"JL Whitwell","year":"2001","unstructured":"Whitwell, J. L., Crum, W. R., Watt, H. C. & Fox, N. C. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. American Journal of Neuroradiology 22, 1483\u20131489 (2001).","journal-title":"AJNR. Am. J. Neuroradiol."},{"key":"21788_CR38","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuroimage.2005.02.018","volume":"26","author":"J Ashburner","year":"2005","unstructured":"Ashburner, J. & Friston, K. J. Unified segmentation. Neuroimage 26, 839\u2013851 (2005).","journal-title":"Neuroimage"},{"key":"21788_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.media.2014.12.003","volume":"21","author":"C Ledig","year":"2015","unstructured":"Ledig, C. et al. Robust whole-brain segmentation: application to traumatic brain injury. Medical Image Analysis 21, 40\u201358 (2015).","journal-title":"Medical image analysis"},{"key":"21788_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fneur.2017.00519","volume":"8","author":"EB Johnson","year":"2017","unstructured":"Johnson, E. B. et al. Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington\u2019s Disease. Frontiers in Neurology 8, 519 (2017).","journal-title":"Frontiers in neurology"},{"key":"21788_CR41","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamaneurol.2016.2038","volume":"73","author":"P Shahim","year":"2016","unstructured":"Shahim, P. et al. Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurol 73, 1308\u20131315 (2016).","journal-title":"JAMA Neurol"},{"key":"21788_CR42","doi-asserted-by":"publisher","first-page":"243ra286","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger, G. et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine 6, 243ra286 (2014).","journal-title":"Science Translational Medicine"},{"key":"21788_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","volume":"313","author":"B Jones","year":"1996","unstructured":"Jones, B., Jarvis, P., Lewis, J. A. & Ebbutt, A. F. Trials to assess equivalence: the importance of rigorous methods. BMJ 313, 36\u201339 (1996).","journal-title":"BMJ"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21788-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21788-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21788-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T22:21:53Z","timestamp":1671574913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21788-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21788"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21788-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,9]]},"assertion":[{"value":"16 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4260"}}